Brown S, Mendoza N, Bertholf R L, Ross R, Wills M R, Savory J, Krantz K D
Res Commun Chem Pathol Pharmacol. 1986 Jul;53(1):105-16.
The absorption of aluminum was studied in twelve healthy male volunteers over a period of fourteen days in a placebo-controlled, double blind study. All subjects were institutionalized during the study. Eight subjects (treated group) received ascending doses of aceglutamide aluminum (N-acetyl-L-glutamine aluminum complex) administered in multiple daily doses. The remaining four subjects (untreated group) received placebo. Systemic absorption and excretion of aluminum were evaluated by measuring aluminum concentrations in serum, urine and fecal samples. Aluminum concentrations were determined by electrothermal atomic absorption spectrometry. All serum aluminum concentrations were less than 16 micrograms/L for both groups. The mean urinary and fecal aluminum concentrations in the aluminum-treated group were significantly higher than in the untreated group during the study days the drug was administered. The total amount of aluminum (as aceglutamide aluminum) given to each treated subject during the 14 day study period as 3290 mg. The mean total fecal aluminum concentration was 3318 mg for the treated group and 269 mg for the untreated group during the study period. These findings are consistent with the view that some aluminum absorption from the gastrointestinal tract occurred following the administration of the drug. The absorbed aluminum appears to have been rapidly excreted in the urine and the feces.
在一项安慰剂对照的双盲研究中，对12名健康男性志愿者进行了为期14天的铝吸收研究。在研究期间，所有受试者均被安置在机构内。8名受试者（治疗组）接受了递增剂量的醋谷胺铝（N - 乙酰 - L - 谷氨酰胺铝复合物），每日分多次给药。其余4名受试者（未治疗组）接受安慰剂。通过测量血清、尿液和粪便样本中的铝浓度来评估铝的全身吸收和排泄情况。铝浓度通过电热原子吸收光谱法测定。两组的所有血清铝浓度均低于16微克/升。在给药期间，铝治疗组的尿铝和粪铝平均浓度显著高于未治疗组。在为期14天的研究期间，给予每个治疗受试者的铝（以醋谷胺铝形式）总量为3290毫克。在研究期间，治疗组的粪铝平均总浓度为3318毫克，未治疗组为269毫克。这些发现与以下观点一致，即给药后胃肠道发生了一些铝的吸收。吸收的铝似乎已迅速通过尿液和粪便排出。
